SleepRes Secures FDA Clearance for Adaptive KPAP Device to Treat Sleep Apnoea

SleepRes has received US Food and Drug Administration (FDA) 510(k) clearance for its KPAP-powered Kricket positive airway pressure device for the treatment of obstructive sleep apnoea (OSA). Designed for patients weighing more than 66lb, the device can be used across hospitals, institutional settings, sleep centres, and home environments.

Kricket is built on SleepRes’ Kairos positive airway pressure (KPAP) platform, which aims to provide a more adaptive, patient-centric alternative to conventional continuous positive airway pressure (CPAP) therapy. Unlike traditional CPAP devices that deliver fixed pressure, KPAP technology dynamically adjusts pressure throughout the breathing cycle to align with a patient’s natural respiratory patterns and airway behaviour. This approach is intended to improve comfort, reduce therapy-related discomfort, and enhance long-term adherence.

The device supports multiple therapy modes, including KPAP, standard CPAP, and automatic PAP. SleepRes plans to commercially launch Kricket in the first half of 2026 while scaling manufacturing and clinical partnerships.

01-01-2026